Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Urologix (ULGX)

Urologix (ULGX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Urologix 14405 21ST AVE N MINNEAPOLIS MN 55447 USA

www.urologix.com P: 612-475-1400

Description:

Urologix, Inc., based in Minneapolis, develops, manufactures and markets minimally invasive medical products for the treatment of urological disorders. The Company has developed and offers non-surgical, anesthesia-free, catheter-based treatments that use a proprietary cooled microwave technology for the treatment of benign prostatic hyperplasia, a condition that affects more than twenty three million men worldwide. Urologix' products include the CoolWave, Targis and Prostatron control units and the Cooled ThermoCath, Targis and Prostaprobe catheter families. Additionally, Urologix is currently developing CoolMax, its next generation microwave catheter for in-office benign prostatic hyperplasia treatment. All of Urologix' products utilize Cooled ThermoTherapy targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort and provide safe, effective, lasting relief of the symptoms of benign prostatic hyperplasia.

Key Statistics

Overview:

Market Capitalization, $K 0
Enterprise Value, $K 0
Shares Outstanding, K 0
Annual Sales, $ 14,240 K
Annual Net Income, $ -7,610 K
EBIT, $ 0 K
EBITDA, $ 0 K
60-Month Beta 0.07
% of Insider Shareholders 8.50%
% of Institutional Shareholders 0.00%
Float, K 0
% Float 0.00%
Short Volume Ratio 1.00

Growth:

1-Year Return 0.00%
3-Year Return -97.22%
5-Year Return -92.31%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 07/05/16
Earnings Per Share ttm 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

ULGX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -53.44%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.00
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar